Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03111992 · ClinicalTrials.gov registry record · Phase 1
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03111992 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT03111992, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma.
Interventions
- DRUG PDR001
- DRUG LCL161
- DRUG CJM112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2020-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03111992
The ClinicalTrials.gov registry entry for NCT03111992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PDR001 is the first listed.
NCT03111992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03111992 about?
NCT03111992 is a clinical study titled "Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma". The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma.
What is the current status of trial NCT03111992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-12-18. Estimated completion is 2020-03-02.
What interventions are being tested in trial NCT03111992?
The interventions under investigation include: PDR001 (DRUG), LCL161 (DRUG), CJM112 (DRUG).
Who is sponsoring clinical trial NCT03111992?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.